The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Value Outlook For The Kcentra Market Through 2030?
Historical growth was fueled by the extensive use of warfarin, the considerable bleeding risk observed in anticoagulated patients, the prompt integration of PCC products, the need within emergency departments, and the surgical safety requirements of hospitals.
Projected growth during the forecast period is attributable to an expanding elderly demographic using anticoagulants, an uptick in emergency surgical interventions, greater understanding of the advantages offered by PCCs, the proliferation of trauma care facilities, and an increase in the volume of outpatient surgical procedures.
Key trends anticipated in the forecast period involve an escalating need for swift anticoagulation reversal, an increase in urgent hemostasis management, a broadening of therapies for controlling surgical bleeding, more frequent application in trauma and critical care environments, and the reinforcement of coagulation protocols within hospitals.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20122&type=smp
What Primary Factors Are Fueling The Expansion Of The Kcentra Market?
The increasing occurrence of bleeding disorders is anticipated to propel the kcentra market in the future. These disorders, which include conditions like hemophilia, von Willebrand disease (VWD), and acquired coagulopathies, are characterized by an impaired ability of the blood to clot, resulting in extended or excessive bleeding. The growing prevalence of such disorders stems from genetic elements, enhanced diagnostic techniques, and heightened awareness, leading to improved case identification globally. Kcentra, a type of prothrombin complex concentrate, is utilized in addressing bleeding disorders, especially for patients on vitamin K antagonists or those experiencing warfarin-associated bleeding. For example, in December 2023, the World Bleeding Disorders Registry, as reported by the Canada-based World Federation of Hemophilia, documented data from 13,343 individuals with hemophilia across 119 treatment centers in 44 countries in 2023, an increase from 12,296 individuals across 108 centers in 42 countries in 2022. Consequently, the rising prevalence of bleeding disorders acts as a significant driver for the kcentra market. Expanding healthcare expenditure is projected to boost the kcentra market moving forward. Healthcare expenditure encompasses all spending on health-related services, covering investments in medical infrastructure, advanced therapeutic options, emergency services, and surgical procedures. The rise in healthcare expenditure can be attributed to several factors such as an aging population, the prevalence of chronic diseases, elevated service costs, increased demand, technological advancements, rising drug prices, the impact of COVID-19, medical inflation, and income polarization. Regarding Kcentra, healthcare spending is primarily directed towards treatments for the urgent reversal of anticoagulant-induced bleeding, incurring substantial costs when used in critical care and hospital environments. For instance, in May 2024, a report from the UK-based government agency, the Office for National Statistics, indicated that total healthcare expenditure saw a nominal increase of 5.6% from 2022 to 2023, compared to a 0.9% growth rate in 2022. Furthermore, overall long-term health and social care expenditure grew by 2.8% in real terms in 2022. Therefore, the escalating healthcare expenditure is a driving force for the kcentra market.
How Does Segment Analysis Break Down The Kcentra Market Structure?
The kcentra market covered in this report is segmented –
1) By Indication: Urgent Reversal Of Warfarin Therapy, Treatment Of Acquired Coagulation Factor Deficiency, Management Of Major Bleeding Events
2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution
3) By Patient Demographics: Pediatric Patients, Adult Patients, Geriatric Patients
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Outpatient Surgical Centers, Emergency Departments, Specialty Clinics
What Trends Are Shaping The Kcentra Market Structure?
A significant development in the kcentra market involves the clearance of novel treatments like balfaxar (a human prothrombin complex concentrate), which is fostering competitive progress throughout the sector. This therapy, Balfaxar, is specifically developed for the rapid reversal of acquired coagulation factor deficiency resulting from warfarin therapy in adult individuals who need immediate surgical interventions or invasive procedures. As an illustration, during July 2023, Octapharma USA, a pharmaceutical firm based in the US, declared that Balfaxar (prothrombin complex concentrate, human-lens, also recognized as octaplex in Europe and Canada) received clearance from the U.S. Food and Drug Administration (FDA) for the rapid reversal of acquired coagulation factor deficiency, often brought on by vitamin K antagonist (VKA, including warfarin) treatment, in adult patients needing urgent surgery or invasive procedures. The mechanism of action for Balfaxar involves restoring normal blood coagulation by replenishing the clotting factors that become deficient due to warfarin therapy.
Who Are The Leading Firms Participating In The Kcentra Market?
Major companies operating in the kcentra market are CSL Behring
Access The Complete Kcentra Market Report:
https://www.thebusinessresearchcompany.com/report/kcentra-global-market-report
Which Region Accounts For The Highest Share Of The Kcentra Market?
North America was the largest region in the kcentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kcentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model